A kind of controlled release injection of carried fluorouracil and synergis

A slow-release injection, fluorouracil-loaded technology, applied in the field of medicine, can solve the problems of many complications, poor curative effect, difficult operation, etc., and achieve the effects of reducing complications, reducing toxicity, and facilitating drug injection

Inactive Publication Date: 2007-05-09
SHANDONG LANJIN PHARMA +1
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, solid sustained-release implants (Chinese Patent No. ZL96115937.5; ZL97107076.8) and existing sustained-release microspheres for the treatme

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Put 80mg of polyphenylene propane (p-CPP: 20:80 of sebacic acid (SA)) copolymer into the container respectively, then add 100ml of dichloromethane, dissolve and mix well, then add 10 mg of 5-FU and 10 mg of oxaliplatin were re-shaken and spray-dried to prepare microspheres for injection containing 10% 5-FU and 10% oxaliplatin. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection with a viscosity of 360cp-480cp (at 25°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.

Embodiment 2

[0110] Put 80mg of polyphenylpropane (p-CPP: 50:50 of sebacic acid (SA)) copolymer into the container respectively, then add 100ml of dichloromethane, dissolve and mix well, then add 5mg of 5-FU and 15mg of oxaliplatin were re-shaken and spray-dried to prepare microspheres for injection containing 5% 5-FU and 15% oxaliplatin. Then suspend the microspheres in physiological saline containing 1.5% carboxymethylcellulose sodium to prepare the corresponding suspension-type sustained-release injection with a viscosity of 380cp-460cp (at 25°C-30°C). The drug release time of the sustained release injection in physiological saline in vitro is 14-20 days, and the drug release time in mice subcutaneous is about 25-35 days.

Embodiment 3

[0112] The method steps for processing into sustained-release injections are the same as in Example 2, but the difference is that the anti-cancer active ingredients and their weight percentages are: 15% 5-FU and 5% oxaliplatin, suspension-type slow-release injections The viscosity of the release injection is 420cp-520cp (at 25°C-30°C). The release time of the slow-release injection in physiological saline in vitro is 15-22 days, and the release time in mice subcutaneous is about 25-35 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Login to view more

Abstract

A slowly-release anticancer medicine in the form of injection or implant is disclosed. Said slowly-release injection is composed of a special solvent containing suspending aid and the slowly-release microballs consisting anticance medicine, iterstitial hydrolyte and slowly-releasing auxiliary. Said anticancer medicine is chosen from 5-FU, oxaliplatin, etc. Said interstitial hydrolyte is chosen from collagenase, relaxin, etc. Said slowly-releasing auxiliary is chosen from polylactic acid, FAD, polyethanediol, etc.

Description

(1) Technical field [0001] The invention relates to a slow-release injection containing fluorouracil (5-FU) and its synergist and a preparation method thereof, belonging to medicines [0002] technology field. (2) Background technology [0003] As a commonly used chemotherapeutic drug, 5-fluorouracil (5-FU) has been widely used in the treatment of various malignant tumors, and the effect is more obvious. However, its unexpected neurotoxicity greatly limits the application of this drug. Blood vessels, connective tissue, matrix proteins, fibrinoproteins, and collagen in the tumor stroma not only provide scaffolds and essential nutrients for the growth of tumor cells, but also affect the diffusion of chemotherapy drugs around the tumor and in the tumor tissue. Infiltration and diffusion (see Netti et al. "The influence of the status of the extracellular matrix on the drug delivery in solid tumors" "Cancer Research" 60 pp. 2497-503 (2000) (Netti PA, Cancer Res.2000, 60 (9 ): ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/10A61K31/513A61K45/06A61K31/282A61K31/555A61K31/704A61K31/706A61K47/34A61P35/00A61K47/32
Inventor 孔庆忠贺润平
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap